Inovio Pharmaceuticals (INO) Receives a Hold from H.C. Wainwright


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO). The company’s shares closed last Friday at $6.85, close to its 52-week low of $6.49.

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 13.2% and a 52.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as NeuroBo Pharmaceuticals, Bausch Health Companies, and Oramed Pharmaceuticals.

Currently, the analyst consensus on Inovio Pharmaceuticals is a Moderate Buy with an average price target of $16.60, which is a 151.5% upside from current levels. In a report issued on April 15, RBC Capital also maintained a Hold rating on the stock with a $11.00 price target.

See today’s analyst top recommended stocks >>

Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.58 million and GAAP net loss of $24.34 million. In comparison, last year the company earned revenue of $279.5K and had a GAAP net loss of $37.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system’s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts